Perspectives
perspectives
November 3rd, 2026
FAST-EU and the European Biotech Act: What Regulatory Change Means for Clinical Trial Strategy
perspectives
October 27th, 2026
What China’s Drug Development Boom Means for Global Biopharma
perspectives
October 22nd, 2026
The Evolving Role of Tau Imaging in Alzheimer's Disease
perspectives
October 7th, 2026
AI's Impact on Small Biotechs: Why Better Decisions, Not Just Faster Processes, Will Define Success
perspectives
September 29th, 2026
Getting to First-in-Human Faster: What FDA’s New IND Pilot and NAMs Shift Mean for Sponsors
perspectives
September 21st, 2026
From Data to Decisions: Evaluating Bayesian Dynamic Borrowing Before Your Trial Begins
perspectives
September 11th, 2026
Navigating the Future of Clinical Trial Transparency: Balancing AI-Driven Anonymization with Human Oversight
perspectives
September 3rd, 2026
From Signal to System: FDA Approval Does Not Mean Treatment Can Begin the Next Morning
perspectives
August 27th, 2026
Risk-Based Data Management: Moving Beyond Traditional Data Cleaning
perspectives
August 17th, 2026
From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer
perspectives
August 11th, 2026
The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way
perspectives
August 7th, 2026
UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know